EyePoint Pharmaceuticals Inc
9 - 9.41
7.3 - 21.5
Join Discuss about EYPT with like-minded investors
IU Watchlist: Main Watches: $IONQ 50% the last two days monster move - shorts got twisted. Remember front side = thin. Reactive trades = PROACTIVE covers until things settle down and sell side is confirmed ie: LCID today RIVN etc. So, if I short a parabolic and it flushes I will be covering into flushes like RBLX today until it gets HEAVY and confirms. We may still be going $35 + at this rate. Shorts feel incredibly caught. $LCID floated down AHs I am hopeful for $52 + tomorrow then fade off if not - watch $50 open and flush to $45-47 range and could get a solid rebound too. $GGPI thinking this could fill gap if LCID doesn't ramp back and hold - that said over $14.20s if it continues to defend - behave! $GOEV killer today from pre market awesome job. Higher better tomorrow and then maybe into singles. Failed Follow Through: $RIVN higher better and sub $130s $RBLX nice one today looking to join failed follow through $QS nice seller present higher better for back side Continuation: $EYPT feels like shorts twisted - dips vs $17.50s $TRT same deal - any big break outs = sell any flushes = scoop for me as long as over all trend holds. Don't chase break out you'll be buying smart $ sells. $RETO weak open for break out again - those bids soaked and refreshed. $PPSI same thing - figured $8.50-9s on scan last night I do think shorts are trapped still but if it keeps failing it keeps failing respect it. If you are chasing a break out you're asking for it. $SPI watch dips tomorrow vs. $7 I sized out of most but will re scale if it holds well. $SABS impressive move today feels like shorts twisted on low volume. $KZR nice one today opened up huge after the circuit for the exit will look to re scoop all dips vs $12
146 Replies 11 👍 7 🔥
Next Dividend Date
EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 leverages a bioerodible formulation of EyePoint's proprietary Durasert® sustained release technology with vorolanib, a tyrosine kinase inhibitor. Vorolanib provided clear efficacy signals in two prior human trials in wet AMD as an orally delivered therapy with no significant ocular adverse events. EYP-1901 is currently in a Phase 1 clinical trial initially targeting treatment of wet AMD, with the potential for additional indications in diabetic retinopathy and retinal vein occlusion.